Table 6 Concordance index analysis
Characteristics | Overall survival | Progression-free survival |
|---|---|---|
Validation cohort (n = 321) | Validation cohort (n = 321) | |
Fuhrman grade (1–2 vs. 3–4) | 0.4970 (0.4055–0.5884) | 0.4893 (0.3917–0.5869) |
TNM stage (1–2 vs. 3–4) | 0.5265 (0.4153–0.6377) | 0.5217 (0.3989–0.6444) |
T category (T1a–1b vs T2a–T4) | 0.5419 (0.4502–0.6335) | 0.5438 (0.4439–0.6437) |
CD68 (low vs. high) | 0.5616 (0.4802–0.6431) | 0.5420 (0.4546–0.6295) |
CD68 + Fuhrman grade | 0.5236 (0.4557–0.5917) | 0.5194 (0.4480–0.5908) |
CD68 + TNM stage | 0.5450 (0.4743–0.6157) | 0.5404 (0.4653–0.6156) |
CD68 + T category | 0.5462 (0.4795–0.6128) | 0.5451 (0.4748–0.6155) |
FCER1G (low vs. high) | 0.5959 (0.5221–0.6696) | 0.5906 (0.5141–0.6669) |
FCER1G + Fuhrman grade | 0.5537 (0.4922–0.6153) | 0.5653 (0.4992–0.6314) |
FCER1G + TNM stage | 0.5693 (0.5050–0.6335) | 0.5676 (0.5005–0.6348) |
FCER1G + T category | 0.5686 (0.5084–0.6288) | 0.5688 (0.5059–0.6318) |
CD68 + FCER1G | 0.5753 (0.5145–0.6361) | 0.5668 (0.5032–0.6305) |